Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Allegro’s Hydrocelin significantly improves knee osteoarthritis pain and function in clinical trial
1+ hour, 49+ min ago (217+ words) Feasibility trial in Belgium completed recruitment ahead of schedule with last patient treated; three-month data from study are expected in second half of 2026 Liege, Belgium – 9 September 2026 (08:30 CET) – Allegro NV, a biomedical company developing a transformative nanotechnology treatment for osteoarthritis, today…...
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
4+ mon, 2+ week ago (229+ words) Demonstrates ART26.12’s Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year Phase 1 SAD Study Exhibited Excellent Safety with Zero Adverse Events Attributed to ART26.12 These findings are supported by a broader body of evidence…...
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
5+ mon, 4+ day ago (509+ words) First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of Channel Therapeutics, a Pelthos subsidiary DURHAM,…...
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
4+ mon, 3+ week ago (192+ words) Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The London Clinic, reflecting increasing utilization for evaluation of chronic low back pain With more…...
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
5+ mon, 3+ week ago (251+ words) TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well tolerated BERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix…...
Sickle Cell Care Reaches an Inflection Point as Gene Therapy Enthusiasm Rises, but Referral Pathways and Uptake Lag Amid Due to Treatment Burden
5+ mon, 4+ week ago (180+ words) New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime About Patient Chart Dynamix™ About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm…...
AAOS Announces 2026 IDEA Grant Recipients to Foster Welcoming, Accessible, and Responsive Orthopaedic Culture
6+ mon, 3+ week ago (369+ words) The program awarded over $260,000 in grants The IDEA Grant Program funds programs that create and expand pathways for individuals to pursue careers in orthopaedics, nurtures a workforce that reflects patient populations, and expands access to AAOS learning and networking opportunities…...
Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
7+ mon, 1+ week ago (387+ words) THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain…...
Scientists Develop AxioMed Spinal Disc Replacement That Truly Mimics Healthy Human Disc -- A Game-Changer in Spine Surgery
9+ mon, 2+ week ago (511+ words) Landmark biomechanical study shows AxioMed's viscoelastic lumbar disc is the first implant to replicate the natural mechanical behaviors of a human disc, unlocking a new era of motion-preserving spine care. The study, titled "ASTM biomechanical study comparing the AxioMed lumbar…...
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
11+ mon, 1+ week ago (334+ words) -A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026- -SP16 has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat…...